ClinicalTrials.gg
CompletedNCT01332994Updated Sep 7, 2015Results posted

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

A Phase 3 interventional study of rituximab [MabThera/Rituxan] and tocilizumab [RoActemra/Actemra] in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 83 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-09-07.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
519
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.

Enrollment
15th of 110
519 · median 97
Started
2011
with 13 others
Phase 3
65 of 110
none open now
Registered
51st of 110
by date
Lead sponsor
67 of 110
Hoffmann-La Roche

Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 15th largest by enrollment, is one of 14 that started in 2011, is one of 65 in phase 3, and was the 51st registered.

Arthritis, Rheumatoid

3,337 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About tocilizumab

tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing tocilizumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This open-label, multi-center, two-arm, uncontrolled and non-randomized study will evaluate the efficacy and safety of RoActemra/Actemra (tocilizumab) in patients with rheumatoid arthritis. Patients will receive 8 mg/kg RoActemra/Actemra intravenously every 4 weeks for 12 weeks and - if adequately responded - for further 12 weeks. Patients, who show an inadequate clinical response after the first 12 weeks to RoActemra/Actemra, will receive 1 g MabThera/Rituxan (rituximab) intravenously at Week 16 and 18. The anticipated time of study treatment is 32 weeks.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients >/=18 years of age
  • Body weight \< /=130kg
  • Active rheumatoid arthritis of at least 6 months duration, diagnosed according to the American College of Rheumatology (ACR) criteria of 1987
  • Disease Activity Score (DAS28) of >3.2
  • Inadequate clinical response to a stable dose of traditional Disease-Modifying Anti-Rheumatic Drugs (DMARD)
  • Have received permitted DMARDs, one or more; current DMARD therapy must have been at stable dose for at least 4 weeks prior to baseline

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with TNF-inhibitors or other biologic DMARD
  • Major surgery (including joint surgery) within eight weeks prior to baseline or planned major surgery within the study duration
  • Functional class IV (American College of Rheumatology classification)
  • Rheumatic disease other than rheumatoid arthritis
  • History of or current inflammatory joint disease other than rheumatoid arthritis
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
519 participants (actual)

Study arms

  • Experimental
    1

    Drug: tocilizumab [RoActemra/Actemra]

  • Experimental
    2

    Drug: rituximab [MabThera/Rituxan] · Drug: tocilizumab [RoActemra/Actemra]

Interventions

  • Drugrituximab [MabThera/Rituxan]

    Drug page: Rituximab

    1 g intravenously at Week 16 and 18

  • Drugtocilizumab [RoActemra/Actemra]

    Drug page: Tocilizumab

    8 mg/kg intravenously every 4 weeks for 12 weeks.

  • Drugtocilizumab [RoActemra/Actemra]

    Drug page: Tocilizumab

    8 mg/kg intravenously every 4 weeks from Week 16 to Week 28

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Remission at Week 16 According to DAS28

    The DAS28 was calculated as \[0.28 times (x) the square root of number of swollen joints\] plus (+) \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of erythrocyte sedimentation rate (ESR)\] + \[0.014 x Visual Analog Scale (VAS) patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity. Remission was defined as a DAS28 score \<2.6 at the assessment visit.

    Time frame: Week 16

Secondary outcomes

  1. Percentage of Participants Achieving Remission According to DAS28 at Weeks 4, 8, and 12

    The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x VAS patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity. Remission was defined as a DAS28 score \<2.6 at the assessment visit.

    Time frame: Weeks 4, 8, and 12

  2. Percentage of Participants Achieving Remission According to DAS28 at Weeks 16, 20, 24, and 28 Among Participants Treated With 8 Courses of Tocilizumab

    The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x VAS patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity. Remission was defined as a DAS28 score \<2.6 at the assessment visit.

    Time frame: Weeks 16, 20, 24, and 28

  3. Percentage of Participants Achieving Remission According to DAS28 at Week 32 Among Participants Treated With 8 Courses of Tocilizumab

    The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x VAS patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity. Remission was defined as a DAS28 score \<2.6 at the assessment visit.

    Time frame: Week 32

  4. Percentage of Participants Achieving Remission According to DAS28 at Week 32 Among Nonresponding Participants Treated With Rituximab

    The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x VAS patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity. Remission was defined as a DAS28 score \<2.6 at the assessment visit.

    Time frame: Week 32

  5. Percentage of Participants Achieving Low Disease Activity Score (LDAS) According to DAS28

    The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x the patient global assessment of disease activity using a VAS\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity. LDAS was defined as a DAS28 score \<3.2 at the assessment visit.

    Time frame: Week 16

  6. Percentage of Participants Achieving LDAS According to DAS28 Among Among Nonresponding Participants Treated With Rituximab

    The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x the patient global assessment of disease activity using a VAS\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity. LDAS was defined as a DAS28 score \<3.2 at the assessment visit.

    Time frame: Week 32

  7. Percentage of Participants Achieving a Clinically Relevant Reduction From Baseline in DAS28 at Week 16

    The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x VAS patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity. Reductions \>1.2 points from Baseline to the assessment visit were considered clinically relevant.

    Time frame: Baseline and Week 16

  8. Percentage of Participants Achieving a Clinically Relevant Reduction From Baseline in DAS28 at Weeks 4, 8, and 12

    The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x VAS patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity. Reductions \>1.2 points from Baseline to the assessment visit were considered clinically relevant.

    Time frame: Baseline and Weeks 4, 8, and 12

  9. Percentage of Participants Achieving a Clinically Relevant Reduction in DAS28 From Week 16 to Week 32 Among Nonresponding Participants Treated With Rituximab

    The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x VAS patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity. Reductions \>1.2 points from the reference visit (Week 16) to the assessment visit were considered clinically relevant.

    Time frame: Weeks 16 and 32

  10. DAS28 Scores During and After Treatment

    The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x VAS patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity.

    Time frame: Baseline and Weeks 4, 8, 12, 16

  11. DAS28 Scores During and After Treatment Among Participants Treated With 8 Courses of Tocilizumab

    The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x VAS patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity.

    Time frame: Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, and 32

  12. DAS28 Scores During and After Treatment Among Nonresponding Participants Treated With Rituximab

    The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x VAS patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity.

    Time frame: Baseline and Weeks 4, 8, 12, 16, 24, and 32

  13. DAS28 Scores During Safety Follow-Up Among Nonresponding Participants Treated With Rituximab

    The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x VAS patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity.

    Time frame: Weeks 40, 48, 56, and 66

  14. Percentage of Participants Achieving a Response According to European League Against Rheumatism (EULAR) Criteria at Weeks 4, 8, 12 and 16

    Response was determined using EULAR criteria based upon DAS28 absolute scores at the assessment visit and the DAS28 reduction from Baseline. Participants with a score ≤3.2 and reduction of \>1.2 points were assessed as having a 'good' response. Participants with a score \>3.2 with reduction of \>1.2 points, or a score ≤5.1 with reduction of \>0.6 to ≤1.2 points, were assessed as having a 'moderate' response. Participants with a score \>5.1 with reduction of \>0.6 to ≤1.2 points, or any score with reduction ≤0.6 points, were assessed as nonresponders with response recorded as 'none.'

    Time frame: Baseline and Weeks 4, 8, 12, and 16

  15. Percentage of Participants Achieving a Response According to EULAR Criteria at Week 32 Compared to Week 16 Among Nonresponding Participants Treated With Rituximab

    Response was determined using EULAR criteria based upon DAS28 absolute scores at the assessment visit and the DAS28 reduction from the reference visit (Week 16). Participants with a score ≤3.2 and reduction of \>1.2 points were assessed as having a 'good' response. Participants with a score \>3.2 with reduction of \>1.2 points, or a score ≤5.1 with reduction of \>0.6 to ≤1.2 points, were assessed as having a 'moderate' response. Participants with a score \>5.1 with reduction of \>0.6 to ≤1.2 points, or any score with reduction ≤0.6 points, were assessed as nonresponders with response recorded as 'none.'

    Time frame: Weeks 16 and 32

  16. Percentage of Participants Achieving a Response According to EULAR Criteria at Weeks 20, 24, 28, and 32 Among Participants Treated With 8 Courses of Tocilizumab

    Response was determined using EULAR criteria based upon DAS28 absolute scores at the assessment visit and the DAS28 reduction from Baseline. Participants with a score ≤3.2 and reduction of \>1.2 points were assessed as having a 'good' response. Participants with a score \>3.2 with reduction of \>1.2 points, or a score ≤5.1 with reduction of \>0.6 to ≤1.2 points, were assessed as having a 'moderate' response. Participants with a score \>5.1 with reduction of \>0.6 to ≤1.2 points, or any score with reduction ≤0.6 points, were assessed as nonresponders with response recorded as 'none.'

    Time frame: Baseline and Weeks 20, 24, 28, and 32

  17. Percentage of Participants Achieving a Response According to American College of Rheumatology (ACR) Criteria at Weeks 4, 8, 12, and 16

    Response was determined using ACR criteria based upon assessment of 66 joints for swelling and 68 joints for tenderness; joints were classified dichotomously as swollen or not swollen and tender or not tender. Respectively, these assessments were used to generate a swollen joint count (SJC) ranging from 0 to 66 swollen joints and a tender joint count (TJC) ranging from 0 to 68 tender joints. Response was defined as a reduction from Baseline of at least 20% for one of the following: VAS scores for patient-reported pain, patient global assessment of disease activity, or physician global assessment of disease activity, Health Assessment Questionnaire Disability Index (HAQ-DI), or C-reactive protein (CRP); plus a reduction in individual SJC and TJC of 20% (ACR20), 50% (ACR50), or 70% (ACR70). VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.'

    Time frame: Baseline and Weeks 4, 8, 12, and 16

  18. Percentage of Participants Achieving a Response According to ACR Criteria at Week 32 Compared to Week 16 Among Nonresponding Participants Treated With Rituximab

    Response was determined using ACR criteria based upon assessment of 66 joints for swelling and 68 joints for tenderness; joints were classified dichotomously as swollen or not swollen and tender or not tender. Respectively, these assessments were used to generate an SJC ranging from 0 to 66 swollen joints and a TJC ranging from 0 to 68 tender joints. Response was defined as a reduction from the reference visit (Week 16) of at least 20% for one of the following: VAS scores for patient-reported pain, patient global assessment of disease activity, or physician global assessment of disease activity, HAQ-DI, or CRP; plus a reduction in individual SJC and TJC of 20% (ACR20), 50% (ACR50), or 70% (ACR70). VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.'

    Time frame: Weeks 16 and 32

  19. Percentage of Participants Achieving a Response According to ACR Criteria at Weeks 20, 24, 28, and 32 Among Participants Treated With 8 Courses of Tocilizumab

    Response was determined using ACR criteria based upon assessment of 66 joints for swelling and 68 joints for tenderness; joints were classified dichotomously as swollen or not swollen and tender or not tender. Respectively, these assessments were used to generate an SJC ranging from 0 to 66 swollen joints and a TJC ranging from 0 to 68 tender joints. Response was defined as a reduction from Baseline of at least 20% for one of the following: VAS scores for patient-reported pain, patient global assessment of disease activity, or physician global assessment of disease activity, HAQ-DI, or CRP; plus a reduction in individual SJC and TJC of 20% (ACR20), 50% (ACR50), or 70% (ACR70). VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.'

    Time frame: Baseline and Weeks 20, 24, 28, and 32

  20. Change From Baseline in Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) Scores at Weeks 4, 8, 12, and 16

    The CDAI was calculated as \[SJC + TJC + VAS patient global assessment of disease activity + VAS physician global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. The SDAI was determined by adding CRP level to the CDAI score. Scores ranged from 0 to 86, with higher scores also indicating increased disease activity. A reduction in either score at the assessment visit reflects improvement in disease.

    Time frame: Baseline and Weeks 4, 8, 12, and 16

  21. Change From Week 16 to 32 in CDAI and SDAI Scores Among Nonresponding Participants Treated With Rituximab

    The CDAI was calculated as \[SJC + TJC + VAS patient global assessment of disease activity + VAS physician global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. The SDAI was determined by adding CRP level to the CDAI score. Scores ranged from 0 to 86, with higher scores also indicating increased disease activity. A reduction in either score at the assessment visit reflects improvement in disease.

    Time frame: Weeks 16 and 32

  22. Change From Baseline in CDAI and SDAI Scores at Weeks 20, 24, 28, and 32 Among Participants Treated With 8 Courses of Tocilizumab

    The CDAI was calculated as \[SJC + TJC + VAS patient global assessment of disease activity + VAS physician global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. The SDAI was determined by adding CRP level to the CDAI score. Scores ranged from 0 to 86, with higher scores also indicating increased disease activity. A reduction in either score at the assessment visit reflects improvement in disease.

    Time frame: Baseline and Weeks 20, 24, 28, and 32

  23. Change From Baseline in Hemoglobin at Weeks 4, 8, 12, and 16

    Blood samples for laboratory assessments, including hemoglobin level, were collected prior to each dose of study medication. The mean hemoglobin level was determined at Baseline and for assessment visits by averaging the observed hemoglobin level among all participants providing evaluable blood samples. Change from Baseline was calculated as \[mean hemoglobin at the assessment visit minus mean hemoglobin at Baseline\] and expressed in grams per liter (g/L).

    Time frame: Baseline and Weeks 4, 8, 12, and 16

  24. Change From Baseline in CRP at Weeks 4, 8, 12, and 16

    Blood samples for laboratory assessments, including CRP level, were collected prior to each dose of study medication. The mean CRP level was determined at Baseline and for assessment visits by averaging the observed CRP level among all participants providing evaluable blood samples. Change from Baseline was calculated as \[mean CRP at the assessment visit minus mean CRP at Baseline\] and expressed in milligrams per deciliter (mg/dL).

    Time frame: Baseline and Weeks 4, 8, 12, and 16

  25. Change From Baseline in ESR at Weeks 4, 8, 12, and 16

    Blood samples for laboratory assessments, including ESR, were collected prior to each dose of study medication. The mean ESR was determined at Baseline and for assessment visits by averaging the observed ESR among all participants providing evaluable blood samples. Change from Baseline was calculated as \[mean ESR at the assessment visit minus mean ESR at Baseline\] and expressed in millimeters per hour (mm/h).

    Time frame: Baseline and Weeks 4, 8, 12, and 16

  26. Change in Hemoglobin From Week 16 to 32 Among Nonresponding Participants Treated With Rituximab

    Blood samples for laboratory assessments, including hemoglobin level, were collected prior to each dose of study medication. The mean hemoglobin level was determined at Baseline and for assessment visits by averaging the observed hemoglobin level among all participants providing evaluable blood samples. Change was calculated as \[mean hemoglobin at Week 32 minus mean hemoglobin at Week 16\] and expressed in g/L.

    Time frame: Weeks 16 and 32

  27. Change in CRP From Week 16 to 32 Among Nonresponding Participants Treated With Rituximab

    Blood samples for laboratory assessments, including CRP level, were collected prior to each dose of study medication. The mean CRP level was determined at Baseline and for assessment visits by averaging the observed CRP level among all participants providing evaluable blood samples. Change was calculated as \[mean CRP at Week 32 minus mean CRP at Week 16\] and expressed in mg/dL.

    Time frame: Weeks 16 and 32

  28. Change in ESR From Week 16 to 32 Among Nonresponding Participants Treated With Rituximab

    Blood samples for laboratory assessments, including ESR, were collected prior to each dose of study medication. The mean ESR was determined at Baseline and for assessment visits by averaging the observed ESR among all participants providing evaluable blood samples. Change was calculated as \[mean ESR at Week 32 minus mean ESR at Week 16\] and expressed in mm/h.

    Time frame: Weeks 16 and 32

  29. Change From Baseline in Hemoglobin at Weeks 20, 24, 28, and 32 Among Participants Treated With 8 Courses of Tocilizumab

    Blood samples for laboratory assessments, including hemoglobin level, were collected prior to each dose of study medication. The mean hemoglobin level was determined at Baseline and for assessment visits by averaging the observed hemoglobin level among all participants providing evaluable blood samples. Change from Baseline was calculated as \[mean hemoglobin at the assessment visit minus mean hemoglobin at Baseline\] and expressed in g/L.

    Time frame: Baseline and Weeks 20, 24, 28, and 32

  30. Change From Baseline in CRP at Weeks 20, 24, 28, and 32 Among Participants Treated With 8 Courses of Tocilizumab

    Blood samples for laboratory assessments, including CRP level, were collected prior to each dose of study medication. The mean CRP level was determined at Baseline and for assessment visits by averaging the observed CRP level among all participants providing evaluable blood samples. Change from Baseline was calculated as \[mean CRP at the assessment visit minus mean CRP at Baseline\] and expressed in mg/dL.

    Time frame: Baseline and Weeks 20, 24, 28, and 32

  31. Change From Baseline in ESR at Weeks 20, 24, 28, and 32 Among Participants Treated With 8 Courses of Tocilizumab

    Blood samples for laboratory assessments, including ESR, were collected prior to each dose of study medication. The mean ESR was determined at Baseline and for assessment visits by averaging the observed ESR among all participants providing evaluable blood samples. Change from Baseline was calculated as \[mean ESR at the assessment visit minus mean ESR at Baseline\] and expressed in mm/h.

    Time frame: Baseline and Weeks 20, 24, 28, and 32

  32. Percentage of Participants Withdrawing From the Study for Insufficient Therapeutic Response

    Study discontinuation was documented by reason for each participant prematurely withdrawing from the study. The percentage of participants was calculated as the number withdrawing for insufficient therapeutic response divided by the total number of participants who began treatment.

    Time frame: Baseline to Week 16

  33. Percentage of B-Cells at Baseline by B-Cell Subpopulation Among Participants With Early Remission

    Blood samples were collected to analyze total B-cell panel via immunophenotyping. Subpopulations were as follows: transitional (cluster of differentiation \[CD\] 19-positive, immunoglobulin (Ig) D-positive, CD38 medium, CD10-positive); naive (CD19-positive, IgD-positive, CD38 medium, CD27-negative); pre-switch memory (CD19-positive, CD27-positive, IgD-positive); post-switch memory (CD19-positive, CD27-positive, IgD-negative); IgG-positive class-switched (CD19-positive, IgG-positive); IgA-positive class-switched (CD19-positive, IgA-positive); double-negative memory (CD19-positive, IgD-negative, CD27-negative); and plasmablasts (CD19-positive, IgD-negative, CD38 high, CD27 high). Naive B-cell compartment was defined as the sum of transitional and naive B-cells. The sum of memory B-cell subsets with or without double-negative B-cells was also determined.

    Time frame: Baseline

  34. Percentage of B-Cells at Baseline by B-Cell Subpopulation Among Participants Treated With 8 Courses of Tocilizumab

    Blood samples were collected to analyze total B-cell panel via immunophenotyping. Subpopulations were as follows: transitional (cluster of differentiation \[CD\] 19-positive, immunoglobulin (Ig) D-positive, CD38 medium, CD10-positive); naive (CD19-positive, IgD-positive, CD38 medium, CD27-negative); pre-switch memory (CD19-positive, CD27-positive, IgD-positive); post-switch memory (CD19-positive, CD27-positive, IgD-negative); IgG-positive class-switched (CD19-positive, IgG-positive); IgA-positive class-switched (CD19-positive, IgA-positive); double-negative memory (CD19-positive, IgD-negative, CD27-negative); and plasmablasts (CD19-positive, IgD-negative, CD38 high, CD27 high). Naive B-cell compartment was defined as the sum of transitional and naive B-cells. The sum of memory B-cell subsets with or without double-negative B-cells was also determined.

    Time frame: Baseline

  35. Percentage of B-Cells at Baseline by B-Cell Subpopulation Among Nonresponding Participants Treated With Rituximab

    Blood samples were collected to analyze total B-cell panel via immunophenotyping. Subpopulations were as follows: transitional (cluster of differentiation \[CD\] 19-positive, immunoglobulin (Ig) D-positive, CD38 medium, CD10-positive); naive (CD19-positive, IgD-positive, CD38 medium, CD27-negative); pre-switch memory (CD19-positive, CD27-positive, IgD-positive); post-switch memory (CD19-positive, CD27-positive, IgD-negative); IgG-positive class-switched (CD19-positive, IgG-positive); IgA-positive class-switched (CD19-positive, IgA-positive); double-negative memory (CD19-positive, IgD-negative, CD27-negative); and plasmablasts (CD19-positive, IgD-negative, CD38 high, CD27 high). Naive B-cell compartment was defined as the sum of transitional and naive B-cells. The sum of memory B-cell subsets with or without double-negative B-cells was also determined.

    Time frame: Baseline

  36. Spearman's Rank Correlation Coefficient Between Percentage of B-Cells at Baseline and Difference in DAS28 Scores Between Baseline and Week 16 Among Participants With Early Remission

    Blood samples were collected to analyze total B-cell panel via immunophenotyping. Subpopulations were as follows: transitional, naïve, pre-switch memory, post-switch memory, IgG-positive class-switched, IgA-positive class-switched, double-negative memory, and plasmablasts. Naive B-cell compartment was defined as the sum of transitional and naive B-cells. The sum of memory B-cell subsets with or without double-negative B-cells was also determined. Extent of disease response, using change from Baseline to Week 16 in DAS28 score, was correlated to the percentage of B-cells within each subpopulation at Baseline. Correlation is indicated by a correlation coefficient (r) \>0.2, with greater values indicating a stronger correlation.

    Time frame: Baseline and Week 16

  37. Spearman's Rank Correlation Coefficient Between Percentage of B-Cells at Baseline and Difference in DAS28 Scores Between Baseline and Weeks 16, 24, and 32 Among Participants Treated With 8 Courses of Tocilizumab

    Blood samples were collected to analyze total B-cell panel via immunophenotyping. Subpopulations were as follows: transitional, naïve, pre-switch memory, post-switch memory, IgG-positive class-switched, IgA-positive class-switched, double-negative memory, and plasmablasts. Naive B-cell compartment was defined as the sum of transitional and naive B-cells. The sum of memory B-cell subsets with or without double-negative B-cells was also determined. Extent of disease response, using change from Baseline in DAS28 score, was correlated to the percentage of B-cells within each subpopulation at Baseline. Correlation is indicated by a correlation coefficient (r) \>0.2, with greater values indicating a stronger correlation.

    Time frame: Baseline and Weeks 16, 24, and 32

  38. Spearman's Rank Correlation Coefficient Between Percentage of B-Cells at Baseline and Difference in DAS28 Scores Between Baseline and Weeks 16, 32, 40, 48, and 66 Among Nonresponding Participants Treated With Rituximab

    Blood samples were collected to analyze total B-cell panel via immunophenotyping. Subpopulations were as follows: transitional, naïve, pre-switch memory, post-switch memory, IgG-positive class-switched, IgA-positive class-switched, double-negative memory, and plasmablasts. Naive B-cell compartment was defined as the sum of transitional and naive B-cells. The sum of memory B-cell subsets with or without double-negative B-cells was also determined. Extent of disease response, using change from Baseline in DAS28 score, was correlated to the percentage of B-cells within each subpopulation at Baseline. Correlation is indicated by a correlation coefficient (r) \>0.2, with greater values indicating a stronger correlation.

    Time frame: Baseline and Weeks 16, 32, 40, 48, and 66

  39. Mean Number of Work Days Missed Per Week

    Work days missed were documented by reason (either rheumatoid arthritis \[RA\] or other reasons) for each participant over the preceding 7-day period. The mean number of work days missed was calculated by averaging the number of days missed per week among all participants.

    Time frame: Baseline and Week 16

  40. Quality of Life as Assessed Using Short Form 36 (SF-36)

    The SF-36 evaluates participant-rated quality of life using 8 domains: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, and mental health. The score for each section is the average of the individual question scores, which are scaled from 0 to 100, with higher scores indicating better functioning. The mean score at each timepoint was determined by averaging the scores among all participants.

    Time frame: Baseline and Week 16

  41. Change From Baseline in Quality of Life as Assessed Using SF-36 at Week 16

    The SF-36 evaluates participant-rated quality of life using 8 domains: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, and mental health. The score for each section is the average of the individual question scores, which are scaled from 0 to 100, with higher scores indicating better functioning. The mean score at each timepoint was determined by averaging the scores among all participants, and the change in each domain score was calculated as \[mean score at Week 16 minus mean score at Baseline\].

    Time frame: Baseline and Week 16

  42. Change From Week 16 to 32 in Quality of Life as Assessed Using SF-36 Scores Among Participants Treated With 8 Courses of Tocilizumab

    The SF-36 evaluates participant-rated quality of life using 8 domains: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, and mental health. The score for each section is the average of the individual question scores, which are scaled from 0 to 100, with higher scores indicating better functioning. The mean score at each timepoint was determined by averaging the scores among all participants, and the change in each domain score was calculated as \[mean score at Week 32 minus mean score at Week 16\].

    Time frame: Weeks 16 and 32

  43. Change From Week 16 to 32 in Quality of Life as Assessed Using SF-36 Scores Among Nonresponding Participants Treated With Rituximab

    The SF-36 evaluates participant-rated quality of life using 8 domains: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, and mental health. The score for each section is the average of the individual question scores, which are scaled from 0 to 100, with higher scores indicating better functioning. The mean score at each timepoint was determined by averaging the scores among all participants, and the change in each domain score was calculated as \[mean score at Week 32 minus mean score at Week 16\].

    Time frame: Weeks 16 and 32

  44. Quality of Life as Assessed Using HAQ-DI

    The HAQ-DI evaluates participant-reported quality of life using 8 categories: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and other common activities such as running errands and performing household chores. Each category contains multiple questions, which are answered using a 4-point scale from 0 to 3. The overall index score is taken as an average of the individual item responses and may range from 0 to 3, where higher scores indicate more difficulty in daily living activities. The mean index score at each timepoint was determined by averaging the scores among all participants.

    Time frame: Baseline and Week 16

  45. Change From Baseline in Quality of Life as Assessed Using HAQ-DI at Week 16

    The HAQ-DI evaluates participant-reported quality of life using 8 categories: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and other common activities such as running errands and performing household chores. Each category contains multiple questions, which are answered using a 4-point scale from 0 to 3. The overall index score is taken as an average of the individual item responses and may range from 0 to 3, where higher scores indicate more difficulty in daily living activities. The mean index score at each timepoint was determined by averaging the scores among all participants, and the change in score was calculated as \[mean score at Week 16 minus mean score at Baseline\].

    Time frame: Baseline and Week 16

  46. Change From Week 16 to 32 in Quality of Life as Assessed Using HAQ-DI Among Participants Treated With 8 Courses of Tocilizumab

    The HAQ-DI evaluates participant-reported quality of life using 8 categories: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and other common activities such as running errands and performing household chores. Each category contains multiple questions, which are answered using a 4-point scale from 0 to 3. The overall index score is taken as an average of the individual item responses and may range from 0 to 3, where higher scores indicate more difficulty in daily living activities. The mean index score at each timepoint was determined by averaging the scores among all participants, and the change in score was calculated as \[mean score at Week 32 minus the mean score at Week 16\].

    Time frame: Weeks 16 and 32

  47. Change From Week 16 to 32 in Quality of Life as Assessed Using HAQ-DI Among Nonresponding Participants Treated With Rituximab

    The HAQ-DI evaluates participant-reported quality of life using 8 categories: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and other common activities such as running errands and performing household chores. Each category contains multiple questions, which are answered using a 4-point scale from 0 to 3. The overall index score is taken as an average of the individual item responses and may range from 0 to 3, where higher scores indicate more difficulty in daily living activities. The mean index score at each timepoint was determined by averaging the scores among all participants, and the change in score was calculated as \[mean score at Week 32 minus the mean score at Week 16\].

    Time frame: Weeks 16 and 32

  48. Percentage of Participants Achieving a Response According to HAQ-DI Criteria

    The HAQ-DI evaluates participant-reported quality of life using 8 categories: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and other common activities such as running errands and performing household chores. Each category contains multiple questions, which are answered using a 4-point scale from 0 to 3. The overall index score is taken as an average of the individual item responses and may range from 0 to 3, where higher scores indicate more difficulty in daily living activities. Response was defined as a change in index score \>0.22 from Baseline to Week 16.

    Time frame: Baseline and Week 16

  49. Quality of Life as Assessed Using Functional Assessment of Chronic Illness Therapy (FACIT)

    The FACIT-F evaluates quality of life using 5 categories: physical well-being (PWB), social/family well-being (SWB), emotional well-being (EWB), functional well-being (FWB), and fatigue (FS). Participants answer each item on a 5-point scale from 0 to 4. The total score is the sum of individual responses across all 5 categories and may range from 0 to 160. The FACIT-General (FACIT-G; range 0 to 108) is the sum of scores for PWB, SWB, EWB, and FWB; the FACIT-Fatigue (FACIT-F) trial outcome index (TOI; range 0 to 108) is the sum of scores for PWB, FWB, and FS; and the FACIT-F fatigue (range 0 to 52) is the sum of scores for the FS only. For derivations of the FACIT-F reported here, higher scores indicate better quality of life. The mean score at each timepoint was determined by averaging scores among all participants.

    Time frame: Baseline and Week 16

  50. Change From Baseline in Quality of Life as Assessed Using FACIT at Week 16

    The FACIT-F evaluates quality of life using 5 categories: PWB, SWB, EWB, FWB, and FS. Participants answer each item on a 5-point scale from 0 to 4. The total score is the sum of individual responses across all 5 categories and may range from 0 to 160. The FACIT-G (range 0 to 108) is the sum of scores for PWB, SWB, EWB, and FWB; the FACIT-F TOI (range 0 to 108) is the sum of scores for PWB, FWB, and FS; and the FACIT-F fatigue (range 0 to 52) is the sum of scores for the FS only. For derivations of the FACIT-F reported here, higher scores indicate better quality of life. The mean score at each timepoint was determined by averaging scores among all participants, and the change in score was calculated as \[mean score at Week 16 minus mean score at Baseline\].

    Time frame: Baseline and Week 16

  51. Change From Week 16 to 32 in Quality of Life as Assessed Using FACIT Among Participants Treated With 8 Courses of Tocilizumab

    The FACIT-F evaluates quality of life using 5 categories: PWB, SWB, EWB, FWB, and FS. Participants answer each item on a 5-point scale from 0 to 4. The total score is the sum of individual responses across all 5 categories and may range from 0 to 160. The FACIT-G (range 0 to 108) is the sum of scores for PWB, SWB, EWB, and FWB; the FACIT-F TOI (range 0 to 108) is the sum of scores for PWB, FWB, and FS; and the FACIT-F fatigue (range 0 to 52) is the sum of scores for the FS only. For derivations of the FACIT-F reported here, higher scores indicate better quality of life. The mean score at each timepoint was determined by averaging scores among all participants, and the change in score was calculated as \[mean score at Week 32 minus mean score at Week 16\].

    Time frame: Weeks 16 and 32

  52. Change From Week 16 to 32 in Quality of Life as Assessed Using FACIT Among Nonresponding Participants Treated With Rituximab

    The FACIT-F evaluates quality of life using 5 categories: PWB, SWB, EWB, FWB, and FS. Participants answer each item on a 5-point scale from 0 to 4. The total score is the sum of individual responses across all 5 categories and may range from 0 to 160. The FACIT-G (range 0 to 108) is the sum of scores for PWB, SWB, EWB, and FWB; the FACIT-F TOI (range 0 to 108) is the sum of scores for PWB, FWB, and FS; and the FACIT-F fatigue (range 0 to 52) is the sum of scores for the FS only. For derivations of the FACIT-F reported here, higher scores indicate better quality of life. The mean score at each timepoint was determined by averaging scores among all participants, and the change in score was calculated as \[mean score at Week 32 minus mean score at Week 16\].

    Time frame: Weeks 16 and 32

07

Results

Posted Sep 7, 2015

Participant flow

Participant flow — Overall Study
MilestoneTocilizumab (TCZ)/TCZ or TCZ/Rituximab (RTX)
Started519
Completed week 16463
Completed week 32 (tcz/tcz)200
Completed week 32 (tcz/rtx)26
Completed week 66 (tcz/rtx)25
Completed448
Not completed71
Withdrew: Adverse event34
Withdrew: Death1
Withdrew: Lack of efficacy1
Withdrew: Lost to follow-up4
Withdrew: Protocol violation6
Withdrew: Withdrawal by subject15
Withdrew: Administrative problem2
Withdrew: Other8

Outcome measures

PrimaryPercentage of Participants Achieving Remission at Week 16 According to DAS28

The DAS28 was calculated as \[0.28 times (x) the square root of number of swollen joints\] plus (+) \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of erythrocyte sedimentation rate (ESR)\] + \[0.014 x Visual Analog Scale (VAS) patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity. Remission was defined as a DAS28 score \<2.6 at the assessment visit.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Remission at Week 16 According to DAS28
percentage of participantsTCZ/TCZ or TCZ/RTX
Percentage of Participants Achieving Remission at Week 16 According to DAS2842.8 (38.5 to 47.2)
Statistical analysis
  • TCZ/TCZ or TCZ/RTX · Exact one-sided binomial test · p = 0.1648 (Exact one-sided binomial test on single proportions with a significance level of alpha equals (=) 0.025. Null hypothesis: Proportion of participants reaching DAS28 remission (\<2.6) at Week 16 is ≤45 percent (%).)
SecondaryPercentage of Participants Achieving Remission According to DAS28 at Weeks 4, 8, and 12

The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x VAS patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity. Remission was defined as a DAS28 score \<2.6 at the assessment visit.

Time frame:
Weeks 4, 8, and 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Remission According to DAS28 at Weeks 4, 8, and 12
percentage of participantsTCZ/TCZ or TCZ/RTX
Week 421.6 (18.1 to 25.4)
Week 840.1 (35.8 to 44.4)
Week 1243.2 (38.9 to 47.5)
SecondaryPercentage of Participants Achieving Remission According to DAS28 at Weeks 16, 20, 24, and 28 Among Participants Treated With 8 Courses of Tocilizumab

The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x VAS patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity. Remission was defined as a DAS28 score \<2.6 at the assessment visit.

Time frame:
Weeks 16, 20, 24, and 28
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Remission According to DAS28 at Weeks 16, 20, 24, and 28 Among Participants Treated With 8 Courses of Tocilizumab
percentage of participantsTCZ/TCZ or TCZ/RTX
Week 161.4 (0.3 to 4.1)
Week 2041.3 (34.6 to 48.2)
Week 2451.2 (44.3 to 58.1)
Week 2855.9 (48.9 to 62.6)
SecondaryPercentage of Participants Achieving Remission According to DAS28 at Week 32 Among Participants Treated With 8 Courses of Tocilizumab

The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x VAS patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity. Remission was defined as a DAS28 score \<2.6 at the assessment visit.

Time frame:
Week 32
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Remission According to DAS28 at Week 32 Among Participants Treated With 8 Courses of Tocilizumab
percentage of participantsTCZ/TCZ or TCZ/RTX
Percentage of Participants Achieving Remission According to DAS28 at Week 32 Among Participants Treated With 8 Courses of Tocilizumab54.9 (48.0 to 61.7)
SecondaryPercentage of Participants Achieving Remission According to DAS28 at Week 32 Among Nonresponding Participants Treated With Rituximab

The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x VAS patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity. Remission was defined as a DAS28 score \<2.6 at the assessment visit.

Time frame:
Week 32
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Remission According to DAS28 at Week 32 Among Nonresponding Participants Treated With Rituximab
percentage of participantsTCZ/TCZ or TCZ/RTX
Percentage of Participants Achieving Remission According to DAS28 at Week 32 Among Nonresponding Participants Treated With Rituximab14.8 (4.2 to 33.7)
SecondaryPercentage of Participants Achieving Low Disease Activity Score (LDAS) According to DAS28

The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x the patient global assessment of disease activity using a VAS\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity. LDAS was defined as a DAS28 score \<3.2 at the assessment visit.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Low Disease Activity Score (LDAS) According to DAS28
percentage of participantsTCZ/TCZ or TCZ/RTX
Percentage of Participants Achieving Low Disease Activity Score (LDAS) According to DAS2868.8 (64.6 to 72.8)
SecondaryPercentage of Participants Achieving LDAS According to DAS28 Among Among Nonresponding Participants Treated With Rituximab

The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x the patient global assessment of disease activity using a VAS\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity. LDAS was defined as a DAS28 score \<3.2 at the assessment visit.

Time frame:
Week 32
Reported as:
Number · percentage of participants
Percentage of Participants Achieving LDAS According to DAS28 Among Among Nonresponding Participants Treated With Rituximab
percentage of participantsTCZ/TCZ or TCZ/RTX
Percentage of Participants Achieving LDAS According to DAS28 Among Among Nonresponding Participants Treated With Rituximab33.3 (16.5 to 54.0)
SecondaryPercentage of Participants Achieving a Clinically Relevant Reduction From Baseline in DAS28 at Week 16

The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x VAS patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity. Reductions \>1.2 points from Baseline to the assessment visit were considered clinically relevant.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Clinically Relevant Reduction From Baseline in DAS28 at Week 16
percentage of participantsTCZ/TCZ or TCZ/RTX
Percentage of Participants Achieving a Clinically Relevant Reduction From Baseline in DAS28 at Week 1686.1 (82.9 to 89.0)
SecondaryPercentage of Participants Achieving a Clinically Relevant Reduction From Baseline in DAS28 at Weeks 4, 8, and 12

The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x VAS patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity. Reductions \>1.2 points from Baseline to the assessment visit were considered clinically relevant.

Time frame:
Baseline and Weeks 4, 8, and 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Clinically Relevant Reduction From Baseline in DAS28 at Weeks 4, 8, and 12
percentage of participantsTCZ/TCZ or TCZ/RTX
Week 474.6 (70.6 to 78.3)
Week 881.5 (77.9 to 84.8)
Week 1283.4 (79.9 to 86.5)
SecondaryPercentage of Participants Achieving a Clinically Relevant Reduction in DAS28 From Week 16 to Week 32 Among Nonresponding Participants Treated With Rituximab

The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x VAS patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity. Reductions \>1.2 points from the reference visit (Week 16) to the assessment visit were considered clinically relevant.

Time frame:
Weeks 16 and 32
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Clinically Relevant Reduction in DAS28 From Week 16 to Week 32 Among Nonresponding Participants Treated With Rituximab
percentage of participantsTCZ/TCZ or TCZ/RTX
Percentage of Participants Achieving a Clinically Relevant Reduction in DAS28 From Week 16 to Week 32 Among Nonresponding Participants Treated With Rituximab37.0 (19.4 to 57.6)
SecondaryDAS28 Scores During and After Treatment

The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x VAS patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity.

Time frame:
Baseline and Weeks 4, 8, 12, 16
Reported as:
Mean · units on a scale
DAS28 Scores During and After Treatment
units on a scaleTCZ/TCZ or TCZ/RTX
Baseline (n=516)5.7 ± 1.0
Week 4 (n=508)3.6 ± 1.3
Week 8 (n=491)3.0 ± 1.4
Week 12 (n=483)2.8 ± 1.4
Week 16 (n=485)2.6 ± 1.3
SecondaryDAS28 Scores During and After Treatment Among Participants Treated With 8 Courses of Tocilizumab

The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x VAS patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity.

Time frame:
Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, and 32
Reported as:
Mean · units on a scale
DAS28 Scores During and After Treatment Among Participants Treated With 8 Courses of Tocilizumab
units on a scaleTCZ/TCZ or TCZ/RTX
Baseline (n=213)6.0 ± 0.9
Week 4 (n=213)4.0 ± 1.2
Week 8 (n=205)3.4 ± 1.2
Week 12 (n=207)3.3 ± 1.1
Week 16 (n=213)3.3 ± 0.6
Week 20 (n=206)2.8 ± 1.0
Week 24 (n=197)2.6 ± 1.1
Week 28 (n=200)2.4 ± 1.1
Week 32 (n=193)2.5 ± 1.2
SecondaryDAS28 Scores During and After Treatment Among Nonresponding Participants Treated With Rituximab

The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x VAS patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity.

Time frame:
Baseline and Weeks 4, 8, 12, 16, 24, and 32
Reported as:
Mean · units on a scale
DAS28 Scores During and After Treatment Among Nonresponding Participants Treated With Rituximab
units on a scaleTCZ/TCZ or TCZ/RTX
Baseline (n=27)5.7 ± 1.0
Week 4 (n=27)4.5 ± 1.2
Week 8 (n=26)4.2 ± 1.5
Week 12 (n=27)4.8 ± 1.6
Week 16 (n=27)5.1 ± 1.2
Week 24 (n=26)4.6 ± 1.4
Week 32 (n=26)4.0 ± 1.5
SecondaryDAS28 Scores During Safety Follow-Up Among Nonresponding Participants Treated With Rituximab

The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x VAS patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity.

Time frame:
Weeks 40, 48, 56, and 66
Reported as:
Mean · units on a scale
DAS28 Scores During Safety Follow-Up Among Nonresponding Participants Treated With Rituximab
units on a scaleTCZ/TCZ or TCZ/RTX
Week 40 (n=26)3.9 ± 1.5
Week 48 (n=25)3.9 ± 1.2
Week 56 (n=22)4.1 ± 1.8
Week 66 (n=25)3.9 ± 1.5
SecondaryPercentage of Participants Achieving a Response According to European League Against Rheumatism (EULAR) Criteria at Weeks 4, 8, 12 and 16

Response was determined using EULAR criteria based upon DAS28 absolute scores at the assessment visit and the DAS28 reduction from Baseline. Participants with a score ≤3.2 and reduction of \>1.2 points were assessed as having a 'good' response. Participants with a score \>3.2 with reduction of \>1.2 points, or a score ≤5.1 with reduction of \>0.6 to ≤1.2 points, were assessed as having a 'moderate' response. Participants with a score \>5.1 with reduction of \>0.6 to ≤1.2 points, or any score with reduction ≤0.6 points, were assessed as nonresponders with response recorded as 'none.'

Time frame:
Baseline and Weeks 4, 8, 12, and 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Response According to European League Against Rheumatism (EULAR) Criteria at Weeks 4, 8, 12 and 16
percentage of participantsTCZ/TCZ or TCZ/RTX
Week 4, Good36.0 (31.9 to 40.3)
Week 4, Moderate47.8 (43.4 to 52.2)
Week 4, None16.2 (13.1 to 19.6)
Week 8, Good56.1 (51.7 to 60.4)
Week 8, Moderate30.6 (26.7 to 34.8)
Week 8, None13.3 (10.5 to 16.5)
Week 12, Good61.1 (56.7 to 65.3)
Week 12, Moderate25.6 (21.9 to 29.6)
Week 12, None13.3 (10.5 to 16.5)
Week 16, Good68.2 (64.0 to 72.2)
Week 16, Moderate20.2 (16.9 to 23.9)
Week 16, None11.6 (8.9 to 14.6)
SecondaryPercentage of Participants Achieving a Response According to EULAR Criteria at Week 32 Compared to Week 16 Among Nonresponding Participants Treated With Rituximab

Response was determined using EULAR criteria based upon DAS28 absolute scores at the assessment visit and the DAS28 reduction from the reference visit (Week 16). Participants with a score ≤3.2 and reduction of \>1.2 points were assessed as having a 'good' response. Participants with a score \>3.2 with reduction of \>1.2 points, or a score ≤5.1 with reduction of \>0.6 to ≤1.2 points, were assessed as having a 'moderate' response. Participants with a score \>5.1 with reduction of \>0.6 to ≤1.2 points, or any score with reduction ≤0.6 points, were assessed as nonresponders with response recorded as 'none.'

Time frame:
Weeks 16 and 32
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Response According to EULAR Criteria at Week 32 Compared to Week 16 Among Nonresponding Participants Treated With Rituximab
percentage of participantsTCZ/TCZ or TCZ/RTX
Good25.9 (11.1 to 46.3)
Moderate29.6 (13.8 to 50.2)
None44.4 (25.5 to 64.7)
SecondaryPercentage of Participants Achieving a Response According to EULAR Criteria at Weeks 20, 24, 28, and 32 Among Participants Treated With 8 Courses of Tocilizumab

Response was determined using EULAR criteria based upon DAS28 absolute scores at the assessment visit and the DAS28 reduction from Baseline. Participants with a score ≤3.2 and reduction of \>1.2 points were assessed as having a 'good' response. Participants with a score \>3.2 with reduction of \>1.2 points, or a score ≤5.1 with reduction of \>0.6 to ≤1.2 points, were assessed as having a 'moderate' response. Participants with a score \>5.1 with reduction of \>0.6 to ≤1.2 points, or any score with reduction ≤0.6 points, were assessed as nonresponders with response recorded as 'none.'

Time frame:
Baseline and Weeks 20, 24, 28, and 32
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Response According to EULAR Criteria at Weeks 20, 24, 28, and 32 Among Participants Treated With 8 Courses of Tocilizumab
percentage of participantsTCZ/TCZ or TCZ/RTX
Week 20, Good65.3 (58.5 to 71.6)
Week 20, Moderate30.0 (24.0 to 36.7)
Week 20, None4.7 (2.3 to 8.5)
Week 24, Good68.1 (61.4 to 74.3)
Week 24, Moderate23.9 (18.4 to 30.3)
Week 24, None8.0 (4.7 to 12.5)
Week 28, Good72.8 (66.3 to 78.6)
Week 28, Moderate19.2 (14.2 to 25.2)
Week 28, None8.0 (4.7 to 12.5)
Week 32, Good66.7 (59.9 to 73.0)
Week 32, Moderate20.7 (15.4 to 26.7)
Week 32, None12.7 (8.5 to 17.9)
SecondaryPercentage of Participants Achieving a Response According to American College of Rheumatology (ACR) Criteria at Weeks 4, 8, 12, and 16

Response was determined using ACR criteria based upon assessment of 66 joints for swelling and 68 joints for tenderness; joints were classified dichotomously as swollen or not swollen and tender or not tender. Respectively, these assessments were used to generate a swollen joint count (SJC) ranging from 0 to 66 swollen joints and a tender joint count (TJC) ranging from 0 to 68 tender joints. Response was defined as a reduction from Baseline of at least 20% for one of the following: VAS scores for patient-reported pain, patient global assessment of disease activity, or physician global assessment of disease activity, Health Assessment Questionnaire Disability Index (HAQ-DI), or C-reactive protein (CRP); plus a reduction in individual SJC and TJC of 20% (ACR20), 50% (ACR50), or 70% (ACR70). VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.'

Time frame:
Baseline and Weeks 4, 8, 12, and 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Response According to American College of Rheumatology (ACR) Criteria at Weeks 4, 8, 12, and 16
percentage of participantsTCZ/TCZ or TCZ/RTX
Week 4, ACR2039.1 (34.9 to 43.5)
Week 4, ACR5015.0 (12.1 to 18.4)
Week 4, ACR705.8 (3.9 to 8.1)
Week 8, ACR2061.1 (56.7 to 65.3)
Week 8, ACR5033.5 (29.5 to 37.8)
Week 8, ACR7015.2 (12.2 to 18.6)
Week 12, ACR2064.0 (59.7 to 68.1)
Week 12, ACR5042.8 (38.5 to 47.2)
Week 12, ACR7020.2 (16.9 to 23.9)
Week 16, ACR2067.1 (62.8 to 71.1)
Week 16, ACR5045.7 (41.3 to 50.1)
Week 16, ACR7024.5 (20.8 to 28.4)
SecondaryPercentage of Participants Achieving a Response According to ACR Criteria at Week 32 Compared to Week 16 Among Nonresponding Participants Treated With Rituximab

Response was determined using ACR criteria based upon assessment of 66 joints for swelling and 68 joints for tenderness; joints were classified dichotomously as swollen or not swollen and tender or not tender. Respectively, these assessments were used to generate an SJC ranging from 0 to 66 swollen joints and a TJC ranging from 0 to 68 tender joints. Response was defined as a reduction from the reference visit (Week 16) of at least 20% for one of the following: VAS scores for patient-reported pain, patient global assessment of disease activity, or physician global assessment of disease activity, HAQ-DI, or CRP; plus a reduction in individual SJC and TJC of 20% (ACR20), 50% (ACR50), or 70% (ACR70). VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.'

Time frame:
Weeks 16 and 32
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Response According to ACR Criteria at Week 32 Compared to Week 16 Among Nonresponding Participants Treated With Rituximab
percentage of participantsTCZ/TCZ or TCZ/RTX
ACR2040.7 (22.4 to 61.2)
ACR5033.3 (16.5 to 54.0)
ACR7022.2 (8.6 to 42.3)
SecondaryPercentage of Participants Achieving a Response According to ACR Criteria at Weeks 20, 24, 28, and 32 Among Participants Treated With 8 Courses of Tocilizumab

Response was determined using ACR criteria based upon assessment of 66 joints for swelling and 68 joints for tenderness; joints were classified dichotomously as swollen or not swollen and tender or not tender. Respectively, these assessments were used to generate an SJC ranging from 0 to 66 swollen joints and a TJC ranging from 0 to 68 tender joints. Response was defined as a reduction from Baseline of at least 20% for one of the following: VAS scores for patient-reported pain, patient global assessment of disease activity, or physician global assessment of disease activity, HAQ-DI, or CRP; plus a reduction in individual SJC and TJC of 20% (ACR20), 50% (ACR50), or 70% (ACR70). VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.'

Time frame:
Baseline and Weeks 20, 24, 28, and 32
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Response According to ACR Criteria at Weeks 20, 24, 28, and 32 Among Participants Treated With 8 Courses of Tocilizumab
percentage of participantsTCZ/TCZ or TCZ/RTX
Week 20, ACR2074.2 (67.8 to 79.9)
Week 20, ACR5045.1 (38.3 to 52.0)
Week 20, ACR7021.1 (15.8 to 27.2)
Week 24, ACR2072.8 (66.3 to 78.6)
Week 24, ACR5049.8 (42.9 to 56.7)
Week 24, ACR7021.6 (16.3 to 27.7)
Week 28, ACR2073.2 (66.8 to 79.1)
Week 28, ACR5053.1 (46.1 to 59.9)
Week 28, ACR7030.5 (24.4 to 37.2)
Week 32, ACR2075.6 (69.2 to 81.2)
Week 32, ACR5054.9 (48.0 to 61.7)
Week 32, ACR7034.3 (27.9 to 41.1)
SecondaryChange From Baseline in Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) Scores at Weeks 4, 8, 12, and 16

The CDAI was calculated as \[SJC + TJC + VAS patient global assessment of disease activity + VAS physician global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. The SDAI was determined by adding CRP level to the CDAI score. Scores ranged from 0 to 86, with higher scores also indicating increased disease activity. A reduction in either score at the assessment visit reflects improvement in disease.

Time frame:
Baseline and Weeks 4, 8, 12, and 16
Reported as:
Mean · units on a scale
Change From Baseline in Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) Scores at Weeks 4, 8, 12, and 16
units on a scaleTCZ/TCZ or TCZ/RTX
CDAI, Week 4 (n=509)-10.9 ± 10.2
CDAI, Week 8 (n=497)-16.5 ± 11.1
CDAI, Week 12 (n=486)-18.3 ± 11.5
CDAI, Week 16 (n=485)-19.4 ± 11.5
SDAI, Week 4 (n=496)-12.3 ± 10.6
SDAI, Week 8 (n=489)-17.9 ± 11.5
SDAI, Week 12 (n=474)-19.7 ± 11.9
SDAI, Week 16 (n=471)-20.7 ± 12.2
SecondaryChange From Week 16 to 32 in CDAI and SDAI Scores Among Nonresponding Participants Treated With Rituximab

The CDAI was calculated as \[SJC + TJC + VAS patient global assessment of disease activity + VAS physician global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. The SDAI was determined by adding CRP level to the CDAI score. Scores ranged from 0 to 86, with higher scores also indicating increased disease activity. A reduction in either score at the assessment visit reflects improvement in disease.

Time frame:
Weeks 16 and 32
Reported as:
Mean · units on a scale
Change From Week 16 to 32 in CDAI and SDAI Scores Among Nonresponding Participants Treated With Rituximab
units on a scaleTCZ/TCZ or TCZ/RTX
CDAI (n=25)-14.2 ± 12.0
SDAI (n=24)-14.0 ± 12.5
SecondaryChange From Baseline in CDAI and SDAI Scores at Weeks 20, 24, 28, and 32 Among Participants Treated With 8 Courses of Tocilizumab

The CDAI was calculated as \[SJC + TJC + VAS patient global assessment of disease activity + VAS physician global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. The SDAI was determined by adding CRP level to the CDAI score. Scores ranged from 0 to 86, with higher scores also indicating increased disease activity. A reduction in either score at the assessment visit reflects improvement in disease.

Time frame:
Baseline and Weeks 20, 24, 28, and 32
Reported as:
Mean · units on a scale
Change From Baseline in CDAI and SDAI Scores at Weeks 20, 24, 28, and 32 Among Participants Treated With 8 Courses of Tocilizumab
units on a scaleTCZ/TCZ or TCZ/RTX
CDAI, Week 20 (n=208)-21.7 ± 11.7
CDAI, Week 24 (n=199)-22.8 ± 11.4
CDAI, Week 28 (n=200)-24.6 ± 12.5
CDAI, Week 32 (n=194)-24.0 ± 13.4
SDAI, Week 20 (n=200)-22.9 ± 12.5
SDAI, Week 24 (n=190)-24.3 ± 12.1
SDAI, Week 28 (n=195)-25.9 ± 13.2
SDAI, Week 32 (n=189)-25.2 ± 14.0
SecondaryChange From Baseline in Hemoglobin at Weeks 4, 8, 12, and 16

Blood samples for laboratory assessments, including hemoglobin level, were collected prior to each dose of study medication. The mean hemoglobin level was determined at Baseline and for assessment visits by averaging the observed hemoglobin level among all participants providing evaluable blood samples. Change from Baseline was calculated as \[mean hemoglobin at the assessment visit minus mean hemoglobin at Baseline\] and expressed in grams per liter (g/L).

Time frame:
Baseline and Weeks 4, 8, 12, and 16
Reported as:
Mean · g/L
Change From Baseline in Hemoglobin at Weeks 4, 8, 12, and 16
g/LTCZ/TCZ or TCZ/RTX
Week 4 (n=509)4.9 ± 7.2
Week 8 (n=496)6.4 ± 8.8
Week 12 (n=483)6.9 ± 9.1
Week 16 (n=477)7.5 ± 9.1
SecondaryChange From Baseline in CRP at Weeks 4, 8, 12, and 16

Blood samples for laboratory assessments, including CRP level, were collected prior to each dose of study medication. The mean CRP level was determined at Baseline and for assessment visits by averaging the observed CRP level among all participants providing evaluable blood samples. Change from Baseline was calculated as \[mean CRP at the assessment visit minus mean CRP at Baseline\] and expressed in milligrams per deciliter (mg/dL).

Time frame:
Baseline and Weeks 4, 8, 12, and 16
Reported as:
Mean · mg/dL
Change From Baseline in CRP at Weeks 4, 8, 12, and 16
mg/dLTCZ/TCZ or TCZ/RTX
Week 4 (n=497)-1.4 ± 1.9
Week 8 (n=492)-1.4 ± 1.9
Week 12 (n=476)-1.4 ± 1.9
Week 16 (n=471)-1.3 ± 1.9
SecondaryChange From Baseline in ESR at Weeks 4, 8, 12, and 16

Blood samples for laboratory assessments, including ESR, were collected prior to each dose of study medication. The mean ESR was determined at Baseline and for assessment visits by averaging the observed ESR among all participants providing evaluable blood samples. Change from Baseline was calculated as \[mean ESR at the assessment visit minus mean ESR at Baseline\] and expressed in millimeters per hour (mm/h).

Time frame:
Baseline and Weeks 4, 8, 12, and 16
Reported as:
Mean · mm/h
Change From Baseline in ESR at Weeks 4, 8, 12, and 16
mm/hTCZ/TCZ or TCZ/RTX
Week 4 (n=507)-25.2 ± 18.1
Week 8 (n=494)-26.6 ± 18.9
Week 12 (n=484)-26.3 ± 19.1
Week 16 (n=484)-27.5 ± 18.7
SecondaryChange in Hemoglobin From Week 16 to 32 Among Nonresponding Participants Treated With Rituximab

Blood samples for laboratory assessments, including hemoglobin level, were collected prior to each dose of study medication. The mean hemoglobin level was determined at Baseline and for assessment visits by averaging the observed hemoglobin level among all participants providing evaluable blood samples. Change was calculated as \[mean hemoglobin at Week 32 minus mean hemoglobin at Week 16\] and expressed in g/L.

Time frame:
Weeks 16 and 32
Reported as:
Mean · g/L
Change in Hemoglobin From Week 16 to 32 Among Nonresponding Participants Treated With Rituximab
g/LTCZ/TCZ or TCZ/RTX
Change in Hemoglobin From Week 16 to 32 Among Nonresponding Participants Treated With Rituximab-2.0 ± 8.3
SecondaryChange in CRP From Week 16 to 32 Among Nonresponding Participants Treated With Rituximab

Blood samples for laboratory assessments, including CRP level, were collected prior to each dose of study medication. The mean CRP level was determined at Baseline and for assessment visits by averaging the observed CRP level among all participants providing evaluable blood samples. Change was calculated as \[mean CRP at Week 32 minus mean CRP at Week 16\] and expressed in mg/dL.

Time frame:
Weeks 16 and 32
Reported as:
Mean · mg/dL
Change in CRP From Week 16 to 32 Among Nonresponding Participants Treated With Rituximab
mg/dLTCZ/TCZ or TCZ/RTX
Change in CRP From Week 16 to 32 Among Nonresponding Participants Treated With Rituximab0.7 ± 1.7
SecondaryChange in ESR From Week 16 to 32 Among Nonresponding Participants Treated With Rituximab

Blood samples for laboratory assessments, including ESR, were collected prior to each dose of study medication. The mean ESR was determined at Baseline and for assessment visits by averaging the observed ESR among all participants providing evaluable blood samples. Change was calculated as \[mean ESR at Week 32 minus mean ESR at Week 16\] and expressed in mm/h.

Time frame:
Weeks 16 and 32
Reported as:
Mean · mm/h
Change in ESR From Week 16 to 32 Among Nonresponding Participants Treated With Rituximab
mm/hTCZ/TCZ or TCZ/RTX
Change in ESR From Week 16 to 32 Among Nonresponding Participants Treated With Rituximab11.5 ± 17.9
SecondaryChange From Baseline in Hemoglobin at Weeks 20, 24, 28, and 32 Among Participants Treated With 8 Courses of Tocilizumab

Blood samples for laboratory assessments, including hemoglobin level, were collected prior to each dose of study medication. The mean hemoglobin level was determined at Baseline and for assessment visits by averaging the observed hemoglobin level among all participants providing evaluable blood samples. Change from Baseline was calculated as \[mean hemoglobin at the assessment visit minus mean hemoglobin at Baseline\] and expressed in g/L.

Time frame:
Baseline and Weeks 20, 24, 28, and 32
Reported as:
Mean · g/L
Change From Baseline in Hemoglobin at Weeks 20, 24, 28, and 32 Among Participants Treated With 8 Courses of Tocilizumab
g/LTCZ/TCZ or TCZ/RTX
Week 20 (n=207)5.5 ± 9.0
Week 24 (n=198)6.6 ± 9.4
Week 28 (n=197)6.9 ± 9.5
Week 32 (n=197)8.3 ± 10.4
SecondaryChange From Baseline in CRP at Weeks 20, 24, 28, and 32 Among Participants Treated With 8 Courses of Tocilizumab

Blood samples for laboratory assessments, including CRP level, were collected prior to each dose of study medication. The mean CRP level was determined at Baseline and for assessment visits by averaging the observed CRP level among all participants providing evaluable blood samples. Change from Baseline was calculated as \[mean CRP at the assessment visit minus mean CRP at Baseline\] and expressed in mg/dL.

Time frame:
Baseline and Weeks 20, 24, 28, and 32
Reported as:
Mean · mg/dL
Change From Baseline in CRP at Weeks 20, 24, 28, and 32 Among Participants Treated With 8 Courses of Tocilizumab
mg/dLTCZ/TCZ or TCZ/RTX
Week 20 (n=200)-1.3 ± 1.9
Week 24 (n=191)-1.4 ± 1.9
Week 28 (n=195)-1.3 ± 1.9
Week 32 (n=192)-1.3 ± 1.9
SecondaryChange From Baseline in ESR at Weeks 20, 24, 28, and 32 Among Participants Treated With 8 Courses of Tocilizumab

Blood samples for laboratory assessments, including ESR, were collected prior to each dose of study medication. The mean ESR was determined at Baseline and for assessment visits by averaging the observed ESR among all participants providing evaluable blood samples. Change from Baseline was calculated as \[mean ESR at the assessment visit minus mean ESR at Baseline\] and expressed in mm/h.

Time frame:
Baseline and Weeks 20, 24, 28, and 32
Reported as:
Mean · mm/h
Change From Baseline in ESR at Weeks 20, 24, 28, and 32 Among Participants Treated With 8 Courses of Tocilizumab
mm/hTCZ/TCZ or TCZ/RTX
Week 20 (n=206)-28.6 ± 17.6
Week 24 (n=197)-29.4 ± 18.0
Week 28 (n=200)-29.4 ± 18.1
Week 32 (n=196)-28.6 ± 20.2
SecondaryPercentage of Participants Withdrawing From the Study for Insufficient Therapeutic Response

Study discontinuation was documented by reason for each participant prematurely withdrawing from the study. The percentage of participants was calculated as the number withdrawing for insufficient therapeutic response divided by the total number of participants who began treatment.

Time frame:
Baseline to Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Withdrawing From the Study for Insufficient Therapeutic Response
percentage of participantsTCZ/TCZ or TCZ/RTX
Percentage of Participants Withdrawing From the Study for Insufficient Therapeutic Response0.2 (0.0 to 1.1)
SecondaryPercentage of B-Cells at Baseline by B-Cell Subpopulation Among Participants With Early Remission

Blood samples were collected to analyze total B-cell panel via immunophenotyping. Subpopulations were as follows: transitional (cluster of differentiation \[CD\] 19-positive, immunoglobulin (Ig) D-positive, CD38 medium, CD10-positive); naive (CD19-positive, IgD-positive, CD38 medium, CD27-negative); pre-switch memory (CD19-positive, CD27-positive, IgD-positive); post-switch memory (CD19-positive, CD27-positive, IgD-negative); IgG-positive class-switched (CD19-positive, IgG-positive); IgA-positive class-switched (CD19-positive, IgA-positive); double-negative memory (CD19-positive, IgD-negative, CD27-negative); and plasmablasts (CD19-positive, IgD-negative, CD38 high, CD27 high). Naive B-cell compartment was defined as the sum of transitional and naive B-cells. The sum of memory B-cell subsets with or without double-negative B-cells was also determined.

Time frame:
Baseline
Reported as:
Median · percentage of B-cells
Percentage of B-Cells at Baseline by B-Cell Subpopulation Among Participants With Early Remission
percentage of B-cellsTCZ/TCZ or TCZ/RTX
Naive B-cell compartment (n=196)61.1 (5.3 to 102.9)
Transitional B-cells (n=196)1.4 (0.1 to 18.8)
Naive B-cells (n=196)58.1 (3.4 to 94.2)
Memory including double-negative (n=46)56.4 (20.2 to 103.5)
Memory excluding double-negative (n=194)46.5 (5.6 to 125.8)
Pre-switch memory B-cells (n=196)11.1 (1.3 to 73.6)
Post-switch memory B-cells (n=196)16.4 (0.8 to 58.1)
IgG-positive class-switched B-cells (n=195)9.9 (0.3 to 42)
IgA-positive class-switched B-cells (n=194)7.4 (0.7 to 35.6)
Double-negative B-cells (n=46)6.1 (2.5 to 16.3)
Plasmablasts (n=196)0.3 (0 to 19.9)
SecondaryPercentage of B-Cells at Baseline by B-Cell Subpopulation Among Participants Treated With 8 Courses of Tocilizumab

Blood samples were collected to analyze total B-cell panel via immunophenotyping. Subpopulations were as follows: transitional (cluster of differentiation \[CD\] 19-positive, immunoglobulin (Ig) D-positive, CD38 medium, CD10-positive); naive (CD19-positive, IgD-positive, CD38 medium, CD27-negative); pre-switch memory (CD19-positive, CD27-positive, IgD-positive); post-switch memory (CD19-positive, CD27-positive, IgD-negative); IgG-positive class-switched (CD19-positive, IgG-positive); IgA-positive class-switched (CD19-positive, IgA-positive); double-negative memory (CD19-positive, IgD-negative, CD27-negative); and plasmablasts (CD19-positive, IgD-negative, CD38 high, CD27 high). Naive B-cell compartment was defined as the sum of transitional and naive B-cells. The sum of memory B-cell subsets with or without double-negative B-cells was also determined.

Time frame:
Baseline
Reported as:
Median · percentage of B-cells
Percentage of B-Cells at Baseline by B-Cell Subpopulation Among Participants Treated With 8 Courses of Tocilizumab
percentage of B-cellsTCZ/TCZ or TCZ/RTX
Naive B-cell compartment (n=197)57.1 (5.6 to 91.2)
Transitional B-cells (n=197)1.3 (0.0 to 13.4)
Naive B-cells (n=197)55.5 (4.7 to 87.1)
Memory including double-negative (n=57)63.2 (18.8 to 113.7)
Memory excluding double-negative (n=196)49.7 (10.9 to 120.1)
Pre-switch memory B-cells (n=197)11.6 (0.9 to 74.1)
Post-switch memory B-cells (n=197)17.2 (2.8 to 52.7)
IgG-positive class-switched B-cells (n=196)10 (0.2 to 38.4)
IgA-positive class-switched B-cells (n=196)8.0 (1.4 to 34.4)
Double-negative B-cells (n=57)6.6 (1.2 to 19.1)
Plasmablasts (n=197)0.3 (0 to 7.6)
SecondaryPercentage of B-Cells at Baseline by B-Cell Subpopulation Among Nonresponding Participants Treated With Rituximab

Blood samples were collected to analyze total B-cell panel via immunophenotyping. Subpopulations were as follows: transitional (cluster of differentiation \[CD\] 19-positive, immunoglobulin (Ig) D-positive, CD38 medium, CD10-positive); naive (CD19-positive, IgD-positive, CD38 medium, CD27-negative); pre-switch memory (CD19-positive, CD27-positive, IgD-positive); post-switch memory (CD19-positive, CD27-positive, IgD-negative); IgG-positive class-switched (CD19-positive, IgG-positive); IgA-positive class-switched (CD19-positive, IgA-positive); double-negative memory (CD19-positive, IgD-negative, CD27-negative); and plasmablasts (CD19-positive, IgD-negative, CD38 high, CD27 high). Naive B-cell compartment was defined as the sum of transitional and naive B-cells. The sum of memory B-cell subsets with or without double-negative B-cells was also determined.

Time frame:
Baseline
Reported as:
Median · percentage of B-cells
Percentage of B-Cells at Baseline by B-Cell Subpopulation Among Nonresponding Participants Treated With Rituximab
percentage of B-cellsTCZ/TCZ or TCZ/RTX
Naive B-cell compartment (n=25)65.9 (9.8 to 85.0)
Transitional B-cells (n=25)1.6 (0.2 to 7.0)
Naive B-cells (n=25)61.9 (5.8 to 83.4)
Memory including double-negative (n=4)45.1 (37.1 to 86.7)
Memory excluding double-negative (n=25)41.5 (21.6 to 139.6)
Pre-switch memory B-cells (n=25)9.1 (2.4 to 36.2)
Post-switch memory B-cells (n=25)16.1 (6.9 to 64.1)
IgG-positive class-switched B-cells (n=25)8.7 (5.0 to 32.7)
IgA-positive class-switched B-cells (n=25)7.7 (3.4 to 29.3)
Double-negative B-cells (n=4)7.5 (5.9 to 9.1)
Plasmablasts (n=25)0.3 (0.0 to 3.2)
SecondarySpearman's Rank Correlation Coefficient Between Percentage of B-Cells at Baseline and Difference in DAS28 Scores Between Baseline and Week 16 Among Participants With Early Remission

Blood samples were collected to analyze total B-cell panel via immunophenotyping. Subpopulations were as follows: transitional, naïve, pre-switch memory, post-switch memory, IgG-positive class-switched, IgA-positive class-switched, double-negative memory, and plasmablasts. Naive B-cell compartment was defined as the sum of transitional and naive B-cells. The sum of memory B-cell subsets with or without double-negative B-cells was also determined. Extent of disease response, using change from Baseline to Week 16 in DAS28 score, was correlated to the percentage of B-cells within each subpopulation at Baseline. Correlation is indicated by a correlation coefficient (r) \>0.2, with greater values indicating a stronger correlation.

Time frame:
Baseline and Week 16
Reported as:
Number · coefficient
Spearman's Rank Correlation Coefficient Between Percentage of B-Cells at Baseline and Difference in DAS28 Scores Between Baseline and Week 16 Among Participants With Early Remission
coefficientTCZ/TCZ or TCZ/RTX
Naive B-cell compartment (n=192)-0.02258
Transitional B-cells (n=192)-0.00949
Naive B-cells (n=192)-0.01920
Memory B-cells (n=62)-0.03148
Pre-switch memory B-cells (n=192)0.03221
Post-switch memory B-cells (n=192)0.05419
IgG-positive class-switched B-cells (n=192)0.08864
IgA-positive class-switched B-cells (n=192)0.01041
Double-negative B-cells (n=62)-0.02134
Plasmablasts (n=192)0.00397
Statistical analysis
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.7559Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.8961Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.7915Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.8081Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.6574Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.4553Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.2215Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.8860Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.8693Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.9564Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
SecondarySpearman's Rank Correlation Coefficient Between Percentage of B-Cells at Baseline and Difference in DAS28 Scores Between Baseline and Weeks 16, 24, and 32 Among Participants Treated With 8 Courses of Tocilizumab

Blood samples were collected to analyze total B-cell panel via immunophenotyping. Subpopulations were as follows: transitional, naïve, pre-switch memory, post-switch memory, IgG-positive class-switched, IgA-positive class-switched, double-negative memory, and plasmablasts. Naive B-cell compartment was defined as the sum of transitional and naive B-cells. The sum of memory B-cell subsets with or without double-negative B-cells was also determined. Extent of disease response, using change from Baseline in DAS28 score, was correlated to the percentage of B-cells within each subpopulation at Baseline. Correlation is indicated by a correlation coefficient (r) \>0.2, with greater values indicating a stronger correlation.

Time frame:
Baseline and Weeks 16, 24, and 32
Reported as:
Number · coefficient
Spearman's Rank Correlation Coefficient Between Percentage of B-Cells at Baseline and Difference in DAS28 Scores Between Baseline and Weeks 16, 24, and 32 Among Participants Treated With 8 Courses of Tocilizumab
coefficientTCZ/TCZ or TCZ/RTX
Week 16, Naive B-cell compartment (n=199)0.00007
Week 16, Transitional B-cells (n=199)-0.06529
Week 16, Naive B-cells (n=199)0.02334
Week 16, Memory B-cells (n=75)0.03478
Week 16, Pre-switch memory B-cells (n=199)-0.01889
Week 16, Post-switch memory B-cells (n=199)-0.04161
Week 16, IgG-positive class-switched (n=199)-0.06235
Week 16, IgA-positive class-switched (n=199)-0.06492
Week 16, Double-negative B-cells (n=75)-0.04352
Week 16, Plasmablasts (n=199)-0.13161
Week 24, Naive B-cell compartment (n=162)-0.18469
Week 24, Transitional B-cells (n=162)-0.21966
Week 24, Naive B-cells (n=162)-0.15683
Week 24, Memory B-cells (n=76)0.15135
Week 24, Pre-switch memory B-cells (n=162)0.08074
Week 24, Post-switch memory B-cells (n=162)0.10798
Week 24, IgG-positive class-switched (n=161)0.10752
Week 24, IgA-positive class-switched (n=162)0.11023
Week 24, Double-negative B-cells (n=76)0.05609
Week 24, Plasmablasts (n=162)0.07468
Week 32, Naive B-cell compartment (n=179)-0.12635
Week 32, Transitional B-cells (n=179)-0.09234
Week 32, Naive B-cells (n=179)-0.11114
Week 32, Memory B-cells (n=88)0.05361
Week 32, Pre-switch memory B-cells (n=179)0.12265
Week 32, Post-switch memory B-cells (n=179)0.05867
Week 32, IgG-positive class-switched (n=181)0.06381
Week 32, IgA-positive class-switched (n=181)0.06036
Week 32, Double-negative B-cells (n=90)-0.06310
Week 32, Plasmablasts (n=179)0.02205
Statistical analysis
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.9993Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.3596Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.7435Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.7671Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.7912Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.5595Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.3817Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.3623Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.7108Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.0639Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.0186Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.0050Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.0463Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.1919Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.3071Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.1714Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.1746Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.1626Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.6304Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.3449Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.0919Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.2189Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.1386Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.6199Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.1019Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.4353Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.3934Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.4196Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.5546Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.7695Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
SecondarySpearman's Rank Correlation Coefficient Between Percentage of B-Cells at Baseline and Difference in DAS28 Scores Between Baseline and Weeks 16, 32, 40, 48, and 66 Among Nonresponding Participants Treated With Rituximab

Blood samples were collected to analyze total B-cell panel via immunophenotyping. Subpopulations were as follows: transitional, naïve, pre-switch memory, post-switch memory, IgG-positive class-switched, IgA-positive class-switched, double-negative memory, and plasmablasts. Naive B-cell compartment was defined as the sum of transitional and naive B-cells. The sum of memory B-cell subsets with or without double-negative B-cells was also determined. Extent of disease response, using change from Baseline in DAS28 score, was correlated to the percentage of B-cells within each subpopulation at Baseline. Correlation is indicated by a correlation coefficient (r) \>0.2, with greater values indicating a stronger correlation.

Time frame:
Baseline and Weeks 16, 32, 40, 48, and 66
Reported as:
Number · coefficient
Spearman's Rank Correlation Coefficient Between Percentage of B-Cells at Baseline and Difference in DAS28 Scores Between Baseline and Weeks 16, 32, 40, 48, and 66 Among Nonresponding Participants Treated With Rituximab
coefficientTCZ/TCZ or TCZ/RTX
Week 16, Naive B-cell compartment (n=24)0.09611
Week 16, Transitional B-cells (n=24)0.08571
Week 16, Naive B-cells (n=24)0.00870
Week 16, Memory B-cells (n=6)-0.60000
Week 16, Pre-switch memory B-cells (n=24)-0.15217
Week 16, Post-switch memory B-cells (n=24)-0.04004
Week 16, IgG-positive class-switched (n=24)-0.07528
Week 16, IgA-positive class-switched (n=24)0.27049
Week 16, Double-negative B-cells (n=6)-0.14286
Week 16, Plasmablasts (n=24)0.13232
Week 32, Naive B-cell compartment (n=0)NA
Week 32, Transitional B-cells (n=0)NA
Week 32, Naive B-cells (n=0)NA
Week 32, Memory B-cells (n=0)NA
Week 32, Pre-switch memory B-cells (n=0)NA
Week 32, Post-switch memory B-cells (n=0)NA
Week 32, IgG-positive class-switched (n=0)NA
Week 32, IgA-positive class-switched (n=0)NA
Week 32, Double-negative B-cells (n=0)NA
Week 32, Plasmablasts (n=0)NA
Week 40, Naive B-cell compartment (n=2)1.00000
Week 40, Transitional B-cells (n=2)-1.00000
Week 40, Naive B-cells (n=2)1.00000
Week 40, Memory B-cells (n=0)NA
Week 40, Pre-switch memory B-cells (n=2)1.00000
Week 40, Post-switch memory B-cells (n=2)1.00000
Week 40, IgG-positive class-switched (n=2)1.00000
Week 40, IgA-positive class-switched (n=2)1.00000
Week 40, Double-negative B-cells (n=0)NA
Week 40, Plasmablasts (n=2)1.00000
Week 48, Naive B-cell compartment (n=5)0.30000
Week 48, Transitional B-cells (n=5)-0.60000
Week 48, Naive B-cells (n=5)0.30000
Week 48, Memory B-cells (n=1)NA
Week 48, Pre-switch memory B-cells (n=5)0.60000
Week 48, Post-switch memory B-cells (n=5)0.20000
Week 48, IgG-positive class-switched (n=5)0.20000
Week 48, IgA-positive class-switched (n=5)0.50000
Week 48, Double-negative B-cells (n=1)NA
Week 48, Plasmablasts (n=5)0.10000
Week 66, Naive B-cell compartment (n=10)0.12727
Week 66, Transitional B-cells (n=10)-0.03030
Week 66, Naive B-cells (n=10)0.04242
Week 66, Memory B-cells (n=3)1.00000
Week 66, Pre-switch memory B-cells (n=10)-0.03030
Week 66, Post-switch memory B-cells (n=10)0.16364
Week 66, IgG-positive class-switched (n=10)0.07295
Week 66, IgA-positive class-switched (n=10)0.12805
Week 66, Double-negative B-cells (n=3)1.00000
Week 66, Plasmablasts (n=10)0.30909
Statistical analysis
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.6551Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.6905Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.9678Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.2080Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.4778Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.8526Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.7266Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.2011Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.7872Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.5377Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.6238Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.2848Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.6238Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.2848Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.7471Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.7471Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.3910Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.8729Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.7261Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.9338Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.9074Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = <0.0001Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.9338Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.6515Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.8413Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.7244Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = <0.0001Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
  • TCZ/TCZ or TCZ/RTX · Spearman Rank-Order Correlation · p = 0.3848Probability values for the Spearman correlation were calculated as \[square root of (n minus 2) x \[square root of (r\^2 divided by 1 minus r\^2)\].
SecondaryMean Number of Work Days Missed Per Week

Work days missed were documented by reason (either rheumatoid arthritis \[RA\] or other reasons) for each participant over the preceding 7-day period. The mean number of work days missed was calculated by averaging the number of days missed per week among all participants.

Time frame:
Baseline and Week 16
Reported as:
Mean · days
Mean Number of Work Days Missed Per Week
daysTCZ/TCZ or TCZ/RTX
Due to RA, Baseline (n=241)1.03 ± 2.30
Due to RA, Week 16 (n=221)0.39 ± 1.51
Due to other reasons, Baseline (n=233)0.14 ± 0.87
Due to other reasons, Week 16 (n=222)0.32 ± 1.26
SecondaryQuality of Life as Assessed Using Short Form 36 (SF-36)

The SF-36 evaluates participant-rated quality of life using 8 domains: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, and mental health. The score for each section is the average of the individual question scores, which are scaled from 0 to 100, with higher scores indicating better functioning. The mean score at each timepoint was determined by averaging the scores among all participants.

Time frame:
Baseline and Week 16
Reported as:
Mean · units on a scale
Quality of Life as Assessed Using Short Form 36 (SF-36)
units on a scaleTCZ/TCZ or TCZ/RTX
Physical functioning, Baseline (n=511)49.6 ± 23.7
Physical functioning, Week 16 (n=473)64.1 ± 25.5
Role (physical), Baseline (n=508)12.9 ± 18.1
Role (physical), Week 16 (n=472)29.9 ± 21.4
Bodily pain, Baseline (n=512)31.3 ± 18.2
Bodily pain, Week 16 (n=474)55.3 ± 17.8
General health, Baseline (n=504)43.6 ± 16.7
General health, Week 16 (n=468)54.3 ± 18.3
Vitality, Baseline (n=512)44.0 ± 19.7
Vitality, Week 16 (n=474)58.1 ± 20.4
Social functioning, Baseline (n=507)68.1 ± 24.8
Social functioning, Week 16 (n=464)80.1 ± 21.6
Role (emotional), Baseline (n=505)55.9 ± 45.0
Role (emotional), Week 16 (n=472)70.9 ± 42.1
Mental health, Baseline (n=513)63.5 ± 18.7
Mental health, Week 16 (n=474)72.3 ± 17.9
SecondaryChange From Baseline in Quality of Life as Assessed Using SF-36 at Week 16

The SF-36 evaluates participant-rated quality of life using 8 domains: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, and mental health. The score for each section is the average of the individual question scores, which are scaled from 0 to 100, with higher scores indicating better functioning. The mean score at each timepoint was determined by averaging the scores among all participants, and the change in each domain score was calculated as \[mean score at Week 16 minus mean score at Baseline\].

Time frame:
Baseline and Week 16
Reported as:
Mean · units on a scale
Change From Baseline in Quality of Life as Assessed Using SF-36 at Week 16
units on a scaleTCZ/TCZ or TCZ/RTX
Physical functioning (n=466)14.3 ± 21.8
Role (physical) (n=461)17.0 ± 22.0
Bodily pain (n=470)23.9 ± 21.1
General health (n=454)10.4 ± 18.5
Vitality (n=468)13.9 ± 19.3
Social functioning (n=456)12.0 ± 23.8
Role (emotional) (n=459)14.7 ± 46.1
Mental health (n=468)8.7 ± 16.8
SecondaryChange From Week 16 to 32 in Quality of Life as Assessed Using SF-36 Scores Among Participants Treated With 8 Courses of Tocilizumab

The SF-36 evaluates participant-rated quality of life using 8 domains: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, and mental health. The score for each section is the average of the individual question scores, which are scaled from 0 to 100, with higher scores indicating better functioning. The mean score at each timepoint was determined by averaging the scores among all participants, and the change in each domain score was calculated as \[mean score at Week 32 minus mean score at Week 16\].

Time frame:
Weeks 16 and 32
Reported as:
Mean · units on a scale
Change From Week 16 to 32 in Quality of Life as Assessed Using SF-36 Scores Among Participants Treated With 8 Courses of Tocilizumab
units on a scaleTCZ/TCZ or TCZ/RTX
Physical functioning (n=188)3.6 ± 16.6
Role (physical) (n=187)2.0 ± 20.6
Bodily pain (n=188)3.2 ± 16.5
General health (n=184)2.6 ± 14.3
Vitality (n=186)2.7 ± 14.2
Social functioning (n=184)-0.3 ± 19.6
Role (emotional) (n=184)5.5 ± 42.3
Mental health (n=186)0.7 ± 15.3
SecondaryChange From Week 16 to 32 in Quality of Life as Assessed Using SF-36 Scores Among Nonresponding Participants Treated With Rituximab

The SF-36 evaluates participant-rated quality of life using 8 domains: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, and mental health. The score for each section is the average of the individual question scores, which are scaled from 0 to 100, with higher scores indicating better functioning. The mean score at each timepoint was determined by averaging the scores among all participants, and the change in each domain score was calculated as \[mean score at Week 32 minus mean score at Week 16\].

Time frame:
Weeks 16 and 32
Reported as:
Mean · units on a scale
Change From Week 16 to 32 in Quality of Life as Assessed Using SF-36 Scores Among Nonresponding Participants Treated With Rituximab
units on a scaleTCZ/TCZ or TCZ/RTX
Physical functioning (n=26)2.5 ± 20.0
Role (physical) (n=24)-1.0 ± 21.5
Bodily pain (n=26)10.6 ± 20.8
General health (n=24)5.2 ± 18.1
Vitality (n=26)1.0 ± 9.3
Social functioning (n=24)-3.1 ± 17.4
Role (emotional) (n=24)2.8 ± 35.3
Mental health (n=26)3.4 ± 10.7
SecondaryQuality of Life as Assessed Using HAQ-DI

The HAQ-DI evaluates participant-reported quality of life using 8 categories: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and other common activities such as running errands and performing household chores. Each category contains multiple questions, which are answered using a 4-point scale from 0 to 3. The overall index score is taken as an average of the individual item responses and may range from 0 to 3, where higher scores indicate more difficulty in daily living activities. The mean index score at each timepoint was determined by averaging the scores among all participants.

Time frame:
Baseline and Week 16
Reported as:
Mean · units on a scale
Quality of Life as Assessed Using HAQ-DI
units on a scaleTCZ/TCZ or TCZ/RTX
Baseline (n=513)1.24 ± 0.67
Week 16 (n=472)0.75 ± 0.67
SecondaryChange From Baseline in Quality of Life as Assessed Using HAQ-DI at Week 16

The HAQ-DI evaluates participant-reported quality of life using 8 categories: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and other common activities such as running errands and performing household chores. Each category contains multiple questions, which are answered using a 4-point scale from 0 to 3. The overall index score is taken as an average of the individual item responses and may range from 0 to 3, where higher scores indicate more difficulty in daily living activities. The mean index score at each timepoint was determined by averaging the scores among all participants, and the change in score was calculated as \[mean score at Week 16 minus mean score at Baseline\].

Time frame:
Baseline and Week 16
Reported as:
Mean · units on a scale
Change From Baseline in Quality of Life as Assessed Using HAQ-DI at Week 16
units on a scaleTCZ/TCZ or TCZ/RTX
Change From Baseline in Quality of Life as Assessed Using HAQ-DI at Week 16-0.48 ± 0.58
SecondaryChange From Week 16 to 32 in Quality of Life as Assessed Using HAQ-DI Among Participants Treated With 8 Courses of Tocilizumab

The HAQ-DI evaluates participant-reported quality of life using 8 categories: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and other common activities such as running errands and performing household chores. Each category contains multiple questions, which are answered using a 4-point scale from 0 to 3. The overall index score is taken as an average of the individual item responses and may range from 0 to 3, where higher scores indicate more difficulty in daily living activities. The mean index score at each timepoint was determined by averaging the scores among all participants, and the change in score was calculated as \[mean score at Week 32 minus the mean score at Week 16\].

Time frame:
Weeks 16 and 32
Reported as:
Mean · units on a scale
Change From Week 16 to 32 in Quality of Life as Assessed Using HAQ-DI Among Participants Treated With 8 Courses of Tocilizumab
units on a scaleTCZ/TCZ or TCZ/RTX
Change From Week 16 to 32 in Quality of Life as Assessed Using HAQ-DI Among Participants Treated With 8 Courses of Tocilizumab-0.06 ± 0.34
SecondaryChange From Week 16 to 32 in Quality of Life as Assessed Using HAQ-DI Among Nonresponding Participants Treated With Rituximab

The HAQ-DI evaluates participant-reported quality of life using 8 categories: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and other common activities such as running errands and performing household chores. Each category contains multiple questions, which are answered using a 4-point scale from 0 to 3. The overall index score is taken as an average of the individual item responses and may range from 0 to 3, where higher scores indicate more difficulty in daily living activities. The mean index score at each timepoint was determined by averaging the scores among all participants, and the change in score was calculated as \[mean score at Week 32 minus the mean score at Week 16\].

Time frame:
Weeks 16 and 32
Reported as:
Mean · units on a scale
Change From Week 16 to 32 in Quality of Life as Assessed Using HAQ-DI Among Nonresponding Participants Treated With Rituximab
units on a scaleTCZ/TCZ or TCZ/RTX
Change From Week 16 to 32 in Quality of Life as Assessed Using HAQ-DI Among Nonresponding Participants Treated With Rituximab-0.10 ± 0.39
SecondaryPercentage of Participants Achieving a Response According to HAQ-DI Criteria

The HAQ-DI evaluates participant-reported quality of life using 8 categories: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and other common activities such as running errands and performing household chores. Each category contains multiple questions, which are answered using a 4-point scale from 0 to 3. The overall index score is taken as an average of the individual item responses and may range from 0 to 3, where higher scores indicate more difficulty in daily living activities. Response was defined as a change in index score \>0.22 from Baseline to Week 16.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Response According to HAQ-DI Criteria
percentage of participantsTCZ/TCZ or TCZ/RTX
Percentage of Participants Achieving a Response According to HAQ-DI Criteria61.1
SecondaryQuality of Life as Assessed Using Functional Assessment of Chronic Illness Therapy (FACIT)

The FACIT-F evaluates quality of life using 5 categories: physical well-being (PWB), social/family well-being (SWB), emotional well-being (EWB), functional well-being (FWB), and fatigue (FS). Participants answer each item on a 5-point scale from 0 to 4. The total score is the sum of individual responses across all 5 categories and may range from 0 to 160. The FACIT-General (FACIT-G; range 0 to 108) is the sum of scores for PWB, SWB, EWB, and FWB; the FACIT-Fatigue (FACIT-F) trial outcome index (TOI; range 0 to 108) is the sum of scores for PWB, FWB, and FS; and the FACIT-F fatigue (range 0 to 52) is the sum of scores for the FS only. For derivations of the FACIT-F reported here, higher scores indicate better quality of life. The mean score at each timepoint was determined by averaging scores among all participants.

Time frame:
Baseline and Week 16
Reported as:
Mean · units on a scale
Quality of Life as Assessed Using Functional Assessment of Chronic Illness Therapy (FACIT)
units on a scaleTCZ/TCZ or TCZ/RTX
FACIT-F TOI, Baseline (n=498)66.2 ± 20.6
FACIT-F TOI, Week 16 (n=460)80.8 ± 19.3
FACIT-G total, Baseline (n=498)71.1 ± 15.7
FACIT-G total, Week 16 (n=462)82.6 ± 15.9
FACIT-F total, Baseline (n=494)103.8 ± 25.5
FACIT-F total, Week 16 (n=458)121.9 ± 25.3
FACIT-F fatigue, Baseline (n=510)32.7 ± 11.6
FACIT-F fatigue, Week 16 (n=475)39.2 ± 10.6
SecondaryChange From Baseline in Quality of Life as Assessed Using FACIT at Week 16

The FACIT-F evaluates quality of life using 5 categories: PWB, SWB, EWB, FWB, and FS. Participants answer each item on a 5-point scale from 0 to 4. The total score is the sum of individual responses across all 5 categories and may range from 0 to 160. The FACIT-G (range 0 to 108) is the sum of scores for PWB, SWB, EWB, and FWB; the FACIT-F TOI (range 0 to 108) is the sum of scores for PWB, FWB, and FS; and the FACIT-F fatigue (range 0 to 52) is the sum of scores for the FS only. For derivations of the FACIT-F reported here, higher scores indicate better quality of life. The mean score at each timepoint was determined by averaging scores among all participants, and the change in score was calculated as \[mean score at Week 16 minus mean score at Baseline\].

Time frame:
Baseline and Week 16
Reported as:
Mean · units on a scale
Change From Baseline in Quality of Life as Assessed Using FACIT at Week 16
units on a scaleTCZ/TCZ or TCZ/RTX
FACIT-F TOI (n=445)14.2 ± 17.9
FACIT-G total (n=445)10.8 ± 13.6
FACIT-F total (n=439)17.5 ± 21.8
FACIT-F fatigue (n=467)6.6 ± 9.9
SecondaryChange From Week 16 to 32 in Quality of Life as Assessed Using FACIT Among Participants Treated With 8 Courses of Tocilizumab

The FACIT-F evaluates quality of life using 5 categories: PWB, SWB, EWB, FWB, and FS. Participants answer each item on a 5-point scale from 0 to 4. The total score is the sum of individual responses across all 5 categories and may range from 0 to 160. The FACIT-G (range 0 to 108) is the sum of scores for PWB, SWB, EWB, and FWB; the FACIT-F TOI (range 0 to 108) is the sum of scores for PWB, FWB, and FS; and the FACIT-F fatigue (range 0 to 52) is the sum of scores for the FS only. For derivations of the FACIT-F reported here, higher scores indicate better quality of life. The mean score at each timepoint was determined by averaging scores among all participants, and the change in score was calculated as \[mean score at Week 32 minus mean score at Week 16\].

Time frame:
Weeks 16 and 32
Reported as:
Mean · units on a scale
Change From Week 16 to 32 in Quality of Life as Assessed Using FACIT Among Participants Treated With 8 Courses of Tocilizumab
units on a scaleTCZ/TCZ or TCZ/RTX
FACIT-F TOI (n=172)1.7 ± 12.9
FACIT-G total (n=174)1.1 ± 9.2
FACIT-F total (n=170)2.0 ± 15.1
FACIT-F fatigue (n=186)0.8 ± 7.4
SecondaryChange From Week 16 to 32 in Quality of Life as Assessed Using FACIT Among Nonresponding Participants Treated With Rituximab

The FACIT-F evaluates quality of life using 5 categories: PWB, SWB, EWB, FWB, and FS. Participants answer each item on a 5-point scale from 0 to 4. The total score is the sum of individual responses across all 5 categories and may range from 0 to 160. The FACIT-G (range 0 to 108) is the sum of scores for PWB, SWB, EWB, and FWB; the FACIT-F TOI (range 0 to 108) is the sum of scores for PWB, FWB, and FS; and the FACIT-F fatigue (range 0 to 52) is the sum of scores for the FS only. For derivations of the FACIT-F reported here, higher scores indicate better quality of life. The mean score at each timepoint was determined by averaging scores among all participants, and the change in score was calculated as \[mean score at Week 32 minus mean score at Week 16\].

Time frame:
Weeks 16 and 32
Reported as:
Mean · units on a scale
Change From Week 16 to 32 in Quality of Life as Assessed Using FACIT Among Nonresponding Participants Treated With Rituximab
units on a scaleTCZ/TCZ or TCZ/RTX
FACIT-F TOI2.9 ± 9.8
FACIT-G total3.0 ± 8.3
FACIT-F total4.4 ± 12.5
FACIT-F fatigue1.4 ± 5.8

Adverse events

Collected over Up to 66 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TCZ/TCZ or TCZ/RTX—54/519 (10.4%)104/519 (20%)
Most frequent serious events
Showing 10 of 64
Most frequent serious events
EventTCZ/TCZ or TCZ/RTX
BronchitisInfections and infestations3/519
BursitisMusculoskeletal and connective tissue disorders3/519
Abdominal painGastrointestinal disorders2/519
HypersensitivityImmune system disorders2/519
DiverticulitisInfections and infestations2/519
PneumoniaInfections and infestations2/519
FallInjury, poisoning and procedural complications2/519
Rheumatoid arthritisMusculoskeletal and connective tissue disorders2/519
LeukopeniaBlood and lymphatic system disorders1/519
NeutropeniaBlood and lymphatic system disorders1/519
Most frequent other events
Most frequent other events
EventTCZ/TCZ or TCZ/RTX
NasopharyngitisInfections and infestations77/519
HypertensionVascular disorders30/519

Baseline characteristics

Main Intent-to-Treat (ITT) Population: All participants who received at least one dose of TCZ.

Age, Continuous
Age, Continuous(years)TCZ/TCZ or TCZ/RTX
Mean55.7 ± 11.9
Sex: Female, Male
Sex: Female, Male(Participants)TCZ/TCZ or TCZ/RTX
Female352
Male167
08

Study locations

83 sites
  • Aachen, 52064, Germany
  • Bad Aibling, 83043, Germany
  • Bad Bramstedt, 24576, Germany
  • Bad Nauheim, 61231, Germany
  • Bad Staffelstein, 96231, Germany
  • Bayreuth, 95445, Germany
  • Berlin, 10117, Germany
  • Berlin, 10435, Germany
  • Berlin, 12161, Germany
  • Berlin, 12435, Germany
  • Berlin, 13055, Germany
  • Berlin, 13125, Germany
  • Berlin, 14129, Germany
  • Blaubeuren, 89143, Germany
  • Bonn, 53111, Germany
  • Bruchhausen-Vilsen, 27305, Germany
  • Chemnitz, 09130, Germany
  • Donaueschingen, 78166, Germany
  • Dresden, 01067, Germany
  • Dresden, 01097, Germany
  • Dresden, 01109, Germany
  • Dresden, 01307, Germany
  • Düsseldorf, 40217, Germany
  • Düsseldorf, 40225, Germany
  • Erfurt, 99096, Germany
  • Essen, 45239, Germany
  • Frankfurt Am Main, 60590, Germany
  • Freiburg, 79106, Germany
  • Giessen, 35392, Germany
  • Gommern, 39245, Germany
  • Goslar, 38642, Germany
  • Greifswald, 17475, Germany
  • Göttingen, 37075, Germany
  • Halle, 06108, Germany
  • Halle, 06120, Germany
  • Halle, 06128, Germany
  • Hamburg, 20246, Germany
  • Hamburg, 22147, Germany
  • Hamburg, 22767, Germany
  • Hannover, 30625, Germany
  • Heidelberg, 69120, Germany
  • Heidelberg, 69121, Germany
  • Herne, 44652, Germany
  • Hildesheim, 31134, Germany
  • Hofheim, 65719, Germany
  • Jena, 07747, Germany
  • Kiel, 24105, Germany
  • Köln, 50679, Germany
  • Köln, 50924, Germany
  • Köln, 51149, Germany
  • Leipzig, 04103, Germany
  • Leipzig, 04109, Germany
  • Lingen, 49808, Germany
  • Ludwigsfelde, 14974, Germany
  • Mainz, 55131, Germany
  • Muenchen, 80336, Germany
  • Mönchengladbach, 41061, Germany
  • München, 80335, Germany
  • München, 81541, Germany
  • Naumburg, 06628, Germany
  • Naunhof, 04683, Germany
  • Neuss, 41460, Germany
  • Neuss, 41462, Germany
  • Nienburg, 31582, Germany
  • Olsberg, 59939, Germany
  • Osnabrück, 49074, Germany
  • Plochingen, 73207, Germany
  • Potsdam, 14469, Germany
  • Ratingen, 40882, Germany
  • Regensburg, 93053, Germany
  • Rendsburg, 24768, Germany
  • Rheine, 48431, Germany
  • Rostock, 18059, Germany
  • Saarbruecken, 66111, Germany
  • Sendenhorst, 48324, Germany
  • Stuttgart, 70178, Germany
  • Stuttgart, 70372, Germany
  • Traunstein, 83278, Germany
  • Trier, 54292, Germany
  • Tübingen, 72076, Germany
  • Ulm, 89081, Germany
  • Wiesbaden, 65189, Germany
  • Wuerzburg, 97080, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2011, a primary completion of Feb 2014 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2015, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2011
First posted
Apr 11, 2011
Start
Mar 2011
Primary completionActual
Feb 2014
CompletionActual
Feb 2014
Results first posted
Sep 7, 2015
Last update
Sep 7, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 7, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01332994
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Apr 11, 2011
Start date
Mar 2011
Primary completion
Feb 2014
Completion
Feb 2014
Results posted
Sep 7, 2015
Last update
Sep 7, 2015

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion